Attendee search 

eADMET is an expert in the creation of customised computational models for the prediction of ADME/Tox properties of small drug-like molecules. eADMET’s modular approach combines proprietary and selected external algorithms to create customised prediction models (with integrated error estimation) for clients and partners from the pharmaceutical and biotechnology industry.

eADMET’s product portfolio includes:

1. OCHEM - a public accessible reference system and database
2. Validated models for precise prediction of various ADME/Tox parameters
3. User-friendly customized model solutions for specific customer needs
4. Expert consultancy services with respect to model application and interpretations.

New developments include chemogenomic methods and methods for in vitro to in vivo correlations to address toxicity prediction within drug discovery and REACH.

eADMET was founded as a result of GO-Bio project awarded to Dr Tetko with a financial support from High-Tech Gründerfonds (HTGF) and Bayern Kapital. it is a spinout from Helmholtz Centre, Munich.

PSites Pharma is developing the next generation of protein kinase inhibitors. Based on our discovery of a new non-ATP competitive, regulatory  binding site we had build up during the last 12 years a whole proprietary development platform, consisting of a focused library, a special screening and a crystallography platform. This allows us to develop clinical candidates for kinase inhibitors with specificities unknown for small coumpounds for any given ACG kinase target within 3 years.

Psites´s own lead compounds for oncology indications (lung and prostate cancer) had been successfully tested in mice and show a very good safety profile.

Our next financing round which is supported by a EUR 3 M. grant by the German governement will enable us to bring 2 compounds into the clinic and we are looking for partners who will share part of the development costs.

Alternatively we are also offering development collaborations for industrial partners who are interested in getting allosteric compounds for their specific target.

SuppreMol, a privately held biopharmaceutical Company, is developing novel proteins to treat autoimmune diseases. SuppreMol has developed a novel therapeutic concept for the treatment of autoimmune diseases that relies on naturally produced Fc gamma receptors (FcγRs). The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry.

The Company is developing SM101 for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) in Phase II clinical trials. SM101 is designed to be a specific, early onset, long lasting and well tolerated treatment for autoimmune diseases such as ITP, SLE, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS).

Further building its platform of selective immunoregulators, SuppreMol is working on antibody programs targeting Fc receptors and other immunomodulatory molecules for alternative treatment strategies in autoimmune conditions.

BioCrea turns concepts into drug candidates. BioCrea is creating new drugs for the treatment of debilitating diseases of the central nervous system. With industry background and an international leadership team BioCrea provides new, first-in-class drug candidates for pharmaceutical companies.

BioCrea’s ability in inventing new treatments led to partnerships with Boehringer-Ingelheim, Pfizer, Wyeth and GlaxoSmithKline. They validate the company’s technology.

BioCrea is ideally positioned to provide new CNS drugs. Unique expertise and technology was integrated at BioCrea to generate new treatments. BioCrea’s patient-to-screen platform combines patient derived genetic information with the screening process and thus makes the outcome less dependent on biological hypothesis of CNS diseases.

The PROTAGEN GROUP is a leading provider of solutions for the

Pharmaceutical and Biotech industries, supporting drug development towards

personalized medicines and GMP compliant protein characterization services

of outstanding quality.

The PROTAGEN GROUP consists of PROTAGEN AG with a clear focus on

diagnostics, and PROTAGEN Protein Services GmbH (PPS) providing GMP

compliant protein analysis.

PROTAGEN AG has developed the proprietary UNIarray® platform to support

patient stratification and the development of Companion Diagnostics (CDx)

using the diagnostic power of autoantibody signatures in blood. We combine

our outstanding know-how in biostatistics and expertise in Protein arrays and

Luminex technology for the development of novel diagnostic assays. Our R&D

focus is on chronic diseases, e.g. neurodegenerative disorders, endometriosis,

autoimmune diseases such as Rheumatoid Arthritis, Systemic Lupus

Erythematosus and Multiple Sclerosis as well as selected cancer indications,

e.g. Prostate-, Breast-, Ovarian-, Colon- and Pancreatic Cancer.

PROTAGEN Protein Services GmbH (PPS)

is a reliable partner for GMP compliant characterization of biotherapeutics

(NBEs) and biosimilar comparability, including stability and release testing.

PPS combines unique expertise in bioinformatics for protein mass spectrometry

with a long track record in protein chemistry and protein analytics in order to

provide the best quality available. In addition, we provide customer support for

all relevant regulatory issues to match with current regulatory requirements

(FDA, EMA, KFDA) for protein drugs.

eADMET is an expert in the creation of customised computational models for the prediction of ADME/Tox properties of small drug-like molecules. eADMET’s modular approach combines proprietary and selected external algorithms to create customised prediction models (with integrated error estimation) for clients and partners from the pharmaceutical and biotechnology industry.

eADMET’s product portfolio includes:

1. OCHEM - a public accessible reference system and database
2. Validated models for precise prediction of various ADME/Tox parameters
3. User-friendly customized model solutions for specific customer needs
4. Expert consultancy services with respect to model application and interpretations.

New developments include chemogenomic methods and methods for in vitro to in vivo correlations to address toxicity prediction within drug discovery and REACH.

eADMET was founded as a result of GO-Bio project awarded to Dr Tetko with a financial support from High-Tech Gründerfonds (HTGF) and Bayern Kapital. it is a spinout from Helmholtz Centre, Munich.

CEVEC commercializes an innovative platform technology for the production of vaccines and biopharmaceuticals in human cell lines.  

CEVEC’s CAP cells hold high promise for a best-in-class production system for viral vaccines, such as hCMV, Influenza and others, as shown by a recent case study. Compared to leading other cellular production systems (like MDCK) CAP demonstrated outstanding results in view of virus yield, extreme short production cycles and minimal media consumption. CEVEC’s CAP system is suspension based and serum free offering the best starting point for new vaccine production approaches with excellent upscaling possibilities. Being the only remaining independent supplier for human production cell lines, the company sets out to repeat the growth story of Crucell B.V., recently acquired by Johnson & Johnson for 2.4 Bn US$. 

Feasibility studies further demonstrated CAP being a versatile virus production platform with a broad susceptibility for various human-pathogenic human viruses. Commercially significant targets include hCMV, RSV, Influenza, Polio, Measles, AAV, Adenoviruses, Lentiviruses and others. Several lead projects have been identified and planned, including the first human platform for hCMV, together with its partner Vaccine Project Manager, Hannover, Germany.

CEVEC is underway to close another 7-10 Mio. EUR venture round. This investment will be used to push the vaccine lead projects, such as hCMV within 3 years to clinical phase I/IIa results and manage a broad roll-out of its vaccine production technology in order to maximize its company exit value by 2015. Venture investors are still invited to participate in an exciting low-risk and high return growth story. For further information, please click here: www.cevec.com

PSites Pharma is developing the next generation of protein kinase inhibitors. Based on our discovery of a new non-ATP competitive, regulatory  binding site we had build up during the last 12 years a whole proprietary development platform, consisting of a focused library, a special screening and a crystallography platform. This allows us to develop clinical candidates for kinase inhibitors with specificities unknown for small coumpounds for any given ACG kinase target within 3 years.

Psites´s own lead compounds for oncology indications (lung and prostate cancer) had been successfully tested in mice and show a very good safety profile.

Our next financing round which is supported by a EUR 3 M. grant by the German governement will enable us to bring 2 compounds into the clinic and we are looking for partners who will share part of the development costs.

Alternatively we are also offering development collaborations for industrial partners who are interested in getting allosteric compounds for their specific target.